In prostate cancer, Gamitrinib-mediated killing indistinguishably affected androgen-dependent and -independent cell types (Kang et al, 2010; Leav et al, 2010), which may contribute to its activity against TRAMP tumours, often characterised by loss of androgen receptor (Huss et al, 2007) and androgen insensitivity (Kaplan-Lefko et al, 2003). Here, AR is linked to prostate cancer.